For instance, whilst the activation of FKN and/or CX3CR1 signalling may provide novel opportunities for the treatment of Alzheimer's Disease (AD) (84), this does not represent a strategy for neuropathic pain where a blockade of FKN and/or CX3CR1 would be desirable. Here, CX3CR1 is linked to early-onset autosomal dominant Alzheimer disease.